Callan JMB Q3 revenue $1.4M, operating loss $1.9M; expands into food sampling and India

CALLAN JMB INC.

2025-Q3 EPS reported -$1.26 revenue$4,562,604

Revenue $1.4M Q3, $4.6M YTD; operating loss $1.9M Q3, $4.5M YTD.
Entered food sampling sector; signed preliminary agreement for oral drug delivery equipment at Texas cGMP facility.
Formed Indian subsidiary for pharma storage; extended Chicago contract to June 2026 with $1.5M increase ($9.1M total).
Upgraded Sentry Monitoring System to v4.0 with HTML5 for web-based temperature monitoring.
SG&A rose to $2.4M Q3 from public listing costs; cash at $2.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.